Key result
Systemic thrombolytic therapy with rtPA successfully treated massive pulmonary embolism in a 4-year-old boy with acute lymphoblastic leukaemia without bleeding complications.
Why the study?
Does systemic thrombolytic therapy with rtPA resolve massive pulmonary embolism safely in a pediatric patient with acute lymphoblastic leukaemia?
Case Report (n=1)
Does systemic thrombolytic therapy with rtPA resolve massive pulmonary embolism safely in a pediatric patient with acute lymphoblastic leukaemia?
Systemic thrombolytic therapy with rtPA was effective and safe for treating massive pulmonary embolism in a young child with acute lymphoblastic leukaemia.
Answers are grounded in this paper and cite their sources.
May support rtPA for massive PE in pediatric ALL; hypothesis-generating, needs prospective validation.
Acute pulmonary embolism (PE) is a serious complication in association with malignant diseases. We describe the successful treatment of PE applying a systemic thrombolytic therapy in a 4-year-old boy with acute lymphoblastic leukaemia. The thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) 0.1 mg/kg bodyweight per hour for six hours was continued for six days without important side effects. In particular no bleeding complications were observed. Computed tomography with contrast revealed a remarkable regression of the central PE. Without further delays the chemotherapy was resumed.
No takes yet. Share an insight, caveat, or question.
Martin et al. (2014) conducted a case report in Massive pulmonary embolism and acute lymphoblastic leukaemia (n=1). Recombinant tissue plasminogen activator (rtPA) was evaluated on Regression of central PE and bleeding complications. Systemic thrombolytic therapy with rtPA successfully treated massive pulmonary embolism in a 4-year-old boy with acute lymphoblastic leukaemia without bleeding complications.
Synapse has enriched 10 related papers. Consider them for comparative context: